Stock NUWE NUWELLIS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Nuwellis, Inc.

Equities

NUWE

US67113Y4052

Advanced Medical Equipment & Technology

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.1678 USD -41.94% Intraday chart for Nuwellis, Inc. -34.71% -71.11%
Apr. 09 Nuwellis, Inc. Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health CI
Mar. 07 Nuwellis, Inc. Announces Results from Two New Clinical Data Analyses from the AVOID-HF Trial, Which Demonstrate the Benefits of its Aquadex System in Reducing Heart Failure Readmissions at 30 Days CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 4.025 19.07 12.01 5.568 1.896 1.141 -
Enterprise Value (EV) 1 4.025 19.07 12.01 5.568 1.896 1.141 1.141
P/E ratio -0.09 x -0.65 x -0.4 x -0.13 x -0.05 x -0.06 x -0.11 x
Yield - - - - - - -
Capitalization / Revenue 0.73 x 2.56 x 1.52 x 0.65 x 0.21 x 0.11 x 0.09 x
EV / Revenue 0.73 x 2.56 x 1.52 x 0.65 x 0.21 x 0.11 x 0.09 x
EV / EBITDA - - -0.63 x -0.35 x -0.11 x -0.1 x -
EV / FCF - - - - - - -
FCF Yield - - - - - - -
Price to Book - - - - - - -
Nbr of stocks (in thousands) 1.56 27.4 105 519 3,264 6,801 -
Reference price 2 2,584 697.0 114.0 10.72 0.5809 0.1678 0.1678
Announcement Date 3/3/20 3/2/21 3/1/22 2/28/23 3/5/24 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net sales 1 5.511 7.441 7.921 8.543 8.864 10.41 12.9
EBITDA 1 - - -19.04 -15.94 -16.6 -11.5 -
EBIT 1 -18.11 -17.03 -19.53 -17.17 -17.63 -13.92 -12.83
Operating Margin -328.54% -228.84% -246.51% -200.99% -198.89% -133.7% -99.47%
Earnings before Tax (EBT) 1 -18.11 -15.83 -19.57 -14.52 -20.2 -13.82 -12.73
Net income 1 -18.11 -15.84 -19.58 -14.52 -22.63 -17.07 -14.73
Net margin -328.69% -212.82% -247.17% -170.02% -255.27% -163.95% -114.2%
EPS 2 -27,900 -1,067 -287.0 -83.55 -11.52 -2.685 -1.480
Free Cash Flow - - - - - - -
FCF margin - - - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 3/3/20 3/2/21 3/1/22 2/28/23 3/5/24 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 1.853 1.642 1.926 2.213 2.065 2.339 1.826 2.075 2.412 2.551 2.12 2.438 2.8 3.055 3.25
EBITDA 1 -5.124 -4.226 -4.311 -4.2 -3.825 -4.298 -5.584 -4.742 -2.945 -3.327 -3.6 -3.1 -2.5 -2.3 -
EBIT 1 -5.251 -4.331 -4.416 -4.301 -3.92 -4.534 -5.851 -5.022 -3.164 -3.593 -3.976 -3.556 -3.168 -3.223 -3.53
Operating Margin -283.38% -263.76% -229.28% -194.35% -189.83% -193.84% -320.43% -242.02% -131.18% -140.85% -187.48% -145.88% -113.14% -105.5% -108.62%
Earnings before Tax (EBT) 1 -5.27 -4.352 -4.471 -4.284 -3.868 -1.893 -6.483 -4.843 -3.368 -5.507 -3.967 -3.521 -3.096 -3.032 -3.48
Net income 1 -5.272 -4.354 -4.473 -4.286 -3.87 -1.896 -6.485 -4.845 -3.37 -7.927 -4.95 -4.282 -3.894 -3.948 -3.48
Net margin -284.51% -265.16% -232.24% -193.67% -187.41% -81.06% -355.15% -233.49% -139.72% -310.74% -233.46% -175.62% -139.03% -129.23% -107.08%
EPS 2 -75.00 -41.00 -42.00 -41.00 -37.00 -5.000 -5.760 -3.650 -1.810 -2.240 -0.9350 -0.7300 -0.5250 -0.4950 -0.3900
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/9/21 3/1/22 5/10/22 8/9/22 11/8/22 2/28/23 5/9/23 8/8/23 11/7/23 3/5/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net Debt - - - - - - -
Net Cash position - - - - - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow - - - - - - -
ROE (net income / shareholders' equity) - - - - - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share - - - - - - -
Capex 1 - - - 0.12 0.15 0.5 0.6
Capex / Sales - - - 1.43% 1.68% 4.8% 4.65%
Announcement Date 3/3/20 3/2/21 3/1/22 2/28/23 3/5/24 - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Nuwellis, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
0.1678 USD
Average target price
5.25 USD
Spread / Average Target
+3,028.72%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
NUWELLIS, INC. Stock Nuwellis, Inc.
-71.11% 1.14M
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+8.07% 219B
DANAHER CORPORATION Stock Danaher Corporation
+6.59% 183B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+11.26% 133B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+26.57% 108B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+13.35% 52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
-0.62% 48.2B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-0.93% 40.37B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+11.54% 39.35B
RESMED, INC. Stock ResMed, Inc.
+26.76% 32.03B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. NUWE Stock
  4. Financials Nuwellis, Inc.